Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Preferred Stock Liabilities (2018 - 2019)

Bicycle Therapeutics (BCYC) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $54.6 million as the latest value for Q1 2019.

  • For the quarter ending Q1 2019, Preferred Stock Liabilities changed 0.0% year-over-year to $54.6 million, compared with a TTM value of $54.6 million through Mar 2019, changed 0.0%, and an annual FY2018 reading of $25.8 million, down 38.41% over the prior year.
  • Preferred Stock Liabilities was $54.6 million for Q1 2019 at Bicycle Therapeutics, up from $25.8 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $54.6 million in Q1 2018 and bottomed at $25.8 million in Q4 2018.